Uk Mhra Gmp
STRIDES SHASUN LIMITEDSTRIDES SHASUN LIMITED – UK MHRA GMP Certificate UK API 20003 Insp GMP 20003/16179217-0001 [H]
Record Details
This Uk Mhra Gmp record concerns STRIDES SHASUN LIMITED, with an inspection on January 9, 2017, issued by the MHRA, covering drugs.
- Company
- STRIDES SHASUN LIMITED
- Compliance status
- GMPC
- Certificate type
- GMP
- Inspection date
- January 9, 2017
- Issued
- April 28, 2017
- MIA number
- UK API 20003
- Site address
- RS NO. 33 AND 34, MATHUR ROAD, PERIYAKALAPET, PUDUCHERRY, IN 605014, INDIA
- Country
- INDIA
- Products
- Human Medicinal Products
- Manufacturing operations
- [2000011939] IBUPROFEN SODIUM [3000011909] S-(+)-IBUPROFEN [2000011938] IBUPROFEN LYSINE [1000008918] IBUPROFEN [2000017096] IBUPROFEN 90% DIRECT COMPRESSION Active Substances 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES IBUPROFEN SODIUM 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Salt formation, Purification, Crystallisation and Isolation 3.5 General Finishing Steps 3.5.1 Physical Processing Steps Drying, Milling, Blending & Sieving 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing S-(+)-IBUPROFEN 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Salt formation, Purification, Crystallisation and Isolation 3.5 General Finishing Steps 3.5.1 Physical Processing Steps Drying, Milling, Blending & Sieving 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing IBUPROFEN LYSINE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Salt formation, Purification, Crystallisation and Isolation 3.5 General Finishing Steps 3.5.1 Physical Processing Steps Drying, Milling, Blending & Sieving 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing IBUPROFEN 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Oxidation, Purification, Crystallisation & Isolation 3.5 General Finishing Steps 3.5.1 Physical Processing Steps Drying, Milling, Blending & Sieving 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing IBUPROFEN 90% DIRECT COMPRESSION 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Oxidation, Purification, Crystallisation & Isolation 3.5 General Finishing Steps 3.5.1 Physical Processing Steps Drying, Milling, Blending & Sieving 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 Quality Control Testing 3.6.1 Physical / Chemical testing
View Company Profile
ID · aea9c27c-f2ac-49aa-8688-f8f180a3ea4c
Other documents for STRIDES SHASUN LIMITED
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.